Literature DB >> 16330898

The ASCOT trial.

Marvin Moser1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16330898      PMCID： PMC8109301          DOI： 10.1111/j.1524-6175.2005.05298.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN： 1524-6175            Impact factor:   3.738


× No keyword cloud information.
  16 in total

1.  Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial.

Authors:  Björn Dahlöf; Peter S Sever; Neil R Poulter; Hans Wedel; D Gareth Beevers; Mark Caulfield; Rory Collins; Sverre E Kjeldsen; Arni Kristinsson; Gordon T McInnes; Jesper Mehlsen; Markku Nieminen; Eoin O'Brien; Jan Ostergren
Journal:  Lancet       Date:  2005 Sep 10-16       Impact factor: 79.321

2.  An overview of the meta-analyses of the hypertension treatment trials.

Authors:  M Moser; P Hebert; C H Hennekens
Journal:  Arch Intern Med       Date:  1991-07

3.  Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study.

Authors:  T W Gress; F J Nieto; E Shahar; M R Wofford; F L Brancati
Journal:  N Engl J Med       Date:  2000-03-30       Impact factor: 91.245

4.  Persistence of reduction in blood pressure and mortality of participants in the Hypertension Detection and Follow-up Program. Hypertension Detection and Follow-up Program Cooperative Group.

Authors: 
Journal:  JAMA       Date:  1988-04-08       Impact factor: 56.272

Review 5.  Recent evidence on drug therapy of mild to moderate hypertension and decreased risk of coronary heart disease.

Authors:  P R Hebert; M Moser; J Mayer; R J Glynn; C H Hennekens
Journal:  Arch Intern Med       Date:  1993-03-08

6.  The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure.

Authors: 
Journal:  Arch Intern Med       Date:  1997-11-24

7.  Mortality rates after 10.5 years for participants in the Multiple Risk Factor Intervention Trial. Findings related to a priori hypotheses of the trial. The Multiple Risk Factor Intervention Trial Research Group.

Authors: 
Journal:  JAMA       Date:  1990-04-04       Impact factor: 56.272

8.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  JAMA       Date:  2003-05-14       Impact factor: 56.272

9.  The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events in hypertension. Rationale and design.

Authors:  J Mann; S Julius
Journal:  Blood Press       Date:  1998-05       Impact factor: 2.835

10.  Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party.

Authors: 
Journal:  BMJ       Date:  1992-02-15
View more
  4 in total

1.  Blood pressure control and cardiovascular risk reduction.

Authors:  G Antonakoudis; L Poulimenos; K Kifnidis; C Zouras; H Antonakoudis
Journal:  Hippokratia       Date:  2007-07       Impact factor: 0.471

2.  British hypertension society recommends that beta-blockers are no longer indicated as initial treatment of hypertension: has the pendulum swung too far?

Authors:  Michael J Bloch
Journal:  J Clin Hypertens (Greenwich)       Date:  2007-02       Impact factor: 3.738

3.  More confusing messages from the hypertension treatment trials.

Authors:  Marvin Moser
Journal:  J Clin Hypertens (Greenwich)       Date:  2006-01       Impact factor: 3.738

4.  Consensus validation of the FORTA (Fit fOR The Aged) List: a clinical tool for increasing the appropriateness of pharmacotherapy in the elderly.

Authors:  Alexandra M Kuhn-Thiel; Christel Weiß; Martin Wehling
Journal:  Drugs Aging       Date:  2014-02       Impact factor: 3.923
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.